NASDAQ:GRFS - GRIFOLS S A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$19.35 -0.82 (-4.07 %)
(As of 10/19/2018 04:00 PM ET)
Previous Close$19.35
Today's Range$19.25 - $20.2050
52-Week Range$18.69 - $25.18
Volume1.46 million shs
Average Volume1.77 million shs
Market Capitalization$13.77 billion
P/E Ratio17.59
Dividend Yield1.91%
Beta1.21
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GRFS
CUSIPN/A
Phone34-93-571-2200

Debt

Debt-to-Equity Ratio1.52
Current Ratio2.90
Quick Ratio1.12

Price-To-Earnings

Trailing P/E Ratio17.59
Forward P/E Ratio15.99
P/E Growth1.41

Sales & Book Value

Annual Sales$4.88 billion
Price / Sales2.71
Cash Flow$1.3901 per share
Price / Cash13.92
Book Value$6.02 per share
Price / Book3.21

Profitability

EPS (Most Recent Fiscal Year)$1.10
Net Income$749.04 million
Net Margins16.55%
Return on Equity18.32%
Return on Assets6.24%

Miscellaneous

Employees18,296
Outstanding Shares682,820,000
Market Cap$13.77 billion

GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S declared a special dividend on Monday, May 28th. Stockholders of record on Monday, June 4th will be given a dividend of $0.0125 per share on Tuesday, June 12th. This represents a dividend yield of 2.15%. The ex-dividend date of this dividend is Friday, June 1st. View GRIFOLS S A/S's Dividend History.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

GRIFOLS S A/S shares split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were distributed to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

How were GRIFOLS S A/S's earnings last quarter?

GRIFOLS S A/S (NASDAQ:GRFS) posted its quarterly earnings data on Friday, July, 27th. The biotechnology company reported $0.34 earnings per share for the quarter, hitting the consensus estimate of $0.34. The biotechnology company had revenue of $1.31 billion for the quarter, compared to analysts' expectations of $1.35 billion. GRIFOLS S A/S had a return on equity of 18.32% and a net margin of 16.55%. View GRIFOLS S A/S's Earnings History.

When is GRIFOLS S A/S's next earnings date?

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Thursday, November 1st 2018. View Earnings Estimates for GRIFOLS S A/S.

What price target have analysts set for GRFS?

7 Wall Street analysts have issued 12 month target prices for GRIFOLS S A/S's shares. Their predictions range from $20.00 to $20.00. On average, they expect GRIFOLS S A/S's stock price to reach $20.00 in the next year. This suggests a possible upside of 3.4% from the stock's current price. View Analyst Price Targets for GRIFOLS S A/S.

What is the consensus analysts' recommendation for GRIFOLS S A/S?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GRIFOLS S A/S.

Are investors shorting GRIFOLS S A/S?

GRIFOLS S A/S saw a increase in short interest in September. As of September 28th, there was short interest totalling 4,715,453 shares, an increase of 165.9% from the September 14th total of 1,773,438 shares. Based on an average daily trading volume, of 879,163 shares, the short-interest ratio is presently 5.4 days. View GRIFOLS S A/S's Current Options Chain.

Who are some of GRIFOLS S A/S's key competitors?

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the folowing people:
  • Mr. Raimon Grifols Roura, Co-Chief Exec. Officer & Exec. Director (Age 54)
  • Mr. Ramón Riera Roca, COO, Chief Commercial Officer & Exec. Director (Age 63)
  • Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 62)
  • Mr. Víctor Grifols Deu, Co-CEO & Exec. Director (Age 41)
  • Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 60)

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Aperio Group LLC (0.04%).

Which institutional investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Aperio Group LLC.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $19.35.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $13.77 billion and generates $4.88 billion in revenue each year. The biotechnology company earns $749.04 million in net income (profit) each year or $1.10 on an earnings per share basis. GRIFOLS S A/S employs 18,296 workers across the globe.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is http://www.grifols.com.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]


MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  469
MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2018 by MarketBeat.com Staff

Featured Article: What is a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel